Batoclimab approval in China has cleared a commercialization milestone for Harbour BioMed. The company announced on October 23, 2026, that the National Medical Products Administration approved its subcutaneous injection for adults with generalized myasthenia gravis who test positive for anti-acetylcholine receptor antibodies.
Key Takeaways
- The approval covers AChR-antibody-positive adults, rather than every patient with generalized myasthenia gravis.
- NBP Pharma will commercialize batoclimab in Greater China, with Harbour receiving tiered royalties on annual net sales.
- The pivotal trial showed greater sustained symptom improvement than placebo, alongside a higher incidence of peripheral edema.
Table of Contents
- Batoclimab approval shifts focus to commercialization
- Pivotal trial showed sustained symptom improvement
- Safety findings remain part of the treatment picture
- Conclusion
Batoclimab approval shifts focus to commercialization
The authorization covers batoclimab injection at a strength of 170 mg per 1 mL vial. The drug is a fully human monoclonal antibody that targets the neonatal Fc receptor, or FcRn, accelerating the breakdown of IgG antibodies involved in autoimmune disease.
Under an October 2022 licensing agreement, NBP Pharma, a subsidiary of CSPC Pharmaceutical Group, will handle commercialization in mainland China, Hong Kong, Macau and Taiwan. Harbour BioMed will receive tiered royalties based on annual net sales in those markets.
That arrangement makes partner-led sales the route to royalty income for Harbour, rather than direct commercialization by the company. Dragon Merit Holdings, another CSPC subsidiary, is the marketing authorization holder. The announcement did not disclose royalty rates, pricing or a launch date.
| Item | Details |
|---|---|
| Sustained Quantitative Myasthenia Gravis improvement | Batoclimab: 64.2%; placebo: 40.6%; P=0.008. |
| Minimal symptoms at any visit | MG-ADL score of 0 or 1: 25.4% with batoclimab versus 4.7% with placebo; P=0.004. |
| Sustained MG-ADL improvement in the second cycle | Batoclimab: 62.7%; placebo: 36.4%; P=0.002. |
Pivotal trial showed sustained symptom improvement
The approval follows a development program whose earlier milestone was Harbour BioMed’s March 2023 Phase III topline announcement. That announcement said the Chinese study met its primary and key secondary endpoints; it predates the latest regulatory decision.
The approval announcement described a pivotal study conducted at 27 centers in China. Its main study population included patients positive for either AChR antibodies or muscle-specific tyrosine kinase antibodies. The approved indication is narrower, covering AChR-antibody-positive adults.
The primary endpoint measured sustained improvement on the Myasthenia Gravis Activities of Daily Living scale, defined as a reduction of at least three points from baseline lasting at least four weeks during the first treatment cycle.
That endpoint was reached by 58.2% of batoclimab-treated patients versus 31.3% receiving placebo, a difference of 26.9 percentage points, with P=0.001. A treatment effect was observed as early as the second week. Additional secondary results are summarized below.
Safety findings remain part of the treatment picture
Harbour described batoclimab as generally well tolerated. Peripheral edema was the most frequently reported adverse event in the treatment group, occurring in 38.8% of patients versus 4.6% with placebo; all cases were mild or moderate.
Plasma albumin levels decreased during treatment but recovered spontaneously after treatment stopped. These findings sit alongside the efficacy results and are important to understanding the drug’s clinical profile.
Generalized myasthenia gravis is a chronic autoimmune neuromuscular disorder that causes skeletal muscle weakness and can become life-threatening in severe cases. Batoclimab targets the antibody-recycling process rather than treating muscle weakness directly.
Conclusion
The approval moves batoclimab into the commercialization stage for its authorized patient group in China. The next step is availability through NBP Pharma, although the announcement gave no launch timetable or pricing details.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
